MCID: HPT003
MIFTS: 67

Hepatitis a

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Hepatitis a

MalaCards integrated aliases for Hepatitis a:

Name: Hepatitis a 12 76 43 44 15 73
Viral Hepatitis, Type a 12
Viral Hepatitis a 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12549
MeSH 44 D006506
NCIt 50 C3096
SNOMED-CT 68 40468003
ICD10 33 B15.0 B15.9
UMLS 73 C0019159

Summaries for Hepatitis a

MedlinePlus : 43 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Hepatitis is an inflammation of the liver. One type, hepatitis A, is caused by the hepatitis A virus (HAV). The disease spreads through contact with an infected person's stool. You can get it from Eating food made by an infected person who did not wash their hands after using the bathroom Drinking untreated water or eating food washed in untreated water Putting into your mouth a finger or object that came into contact with an infected person's stool Having close contact with an infected person, such as through sex or caring for someone who is ill Most people do not have any symptoms. If you do have symptoms, you may feel as if you have the flu. You may also have yellowish eyes and skin, called jaundice. A blood test will show if you have HAV. HAV usually gets better in a few weeks without treatment. However, some people can have symptoms for up to 6 months. Your doctor may suggest medicines to help relieve your symptoms. The hepatitis A vaccine can prevent HAV. Good hygiene can also help. Wash your hands thoroughly before preparing food, after using the toilet, or after changing a diaper. International travelers should be careful about drinking tap water. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Hepatitis a, also known as viral hepatitis, type a, is related to hepatitis and liver disease, and has symptoms including fever, vomiting and fatigue. An important gene associated with Hepatitis a is HAVCR1 (Hepatitis A Virus Cellular Receptor 1), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Influenza A. The drugs Intron A and Cefazolin and Dextrose USP have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 A viral infectious disease that results in inflammation located in liver, has material basis in Hepatitis A virus, which is transmitted by ingestion of contaminated food or water, or transmitted by direct contact with an infected person. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom joint pain, and has symptom jaundice.

Wikipedia : 76 Hepatitis A is an infectious disease of the liver caused by the hepatitis A virus (HAV). Many cases have... more...

Related Diseases for Hepatitis a

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Hepatitis a via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 368)
# Related Disease Score Top Affiliating Genes
1 hepatitis 32.1 AFP F2 GPT HAVCR1 HAVCR2 MAVS
2 liver disease 30.9 ABCB7 AFP ALB F2 GPT SEPSECS
3 cutaneous leishmaniasis 30.7 IFNG IL10 TNF
4 autoimmune hepatitis 30.5 F2 GPT SEPSECS
5 acute liver failure 30.3 ALB F2 GPT
6 infantile liver failure syndrome 1 30.3 ALB F2 GPT
7 viral infectious disease 30.2 GPT IFNG IL10 MAVS TNF
8 alcoholic hepatitis 30.2 ALB F2 GPT IL10 TNF
9 hepatitis d 30.1 F2 GPT
10 typhoid fever 30.1 ALB F2 IFNG TNF
11 hepatitis e 30.1 ALB F2 GPT IFNG TNF
12 hepatitis c 29.9 GPT IFNG MAVS TNF
13 cholecystitis 29.9 ALB F2 GPT
14 viral hepatitis 29.9 ABCB7 AFP ALB F2 GPT SEPSECS
15 hepatitis b 29.9 AFP ALB F2 GPT IFNG TNF
16 liver cirrhosis 29.5 AFP ALB F2 GPT
17 hemophagocytic lymphohistiocytosis 29.5 IFNG IL10 TNF
18 hepatic coma 29.5 ALB F2 GPT
19 malaria 29.4 ALB HAVCR2 IFNG IL10 TNF
20 pertussis 29.4 IL10 TICAM1 TNF
21 epstein-barr virus hepatitis 29.3 ALB F2
22 celiac disease 1 29.3 ALB IFNG IL10 TNF
23 kawasaki disease 29.3 ALB IL10 TNF
24 plasmodium falciparum malaria 29.3 IFNG IL10 TNF
25 cholangitis 29.3 ALB F2 GPT TNF
26 multifocal choroiditis 29.2 IL10 TNF
27 choroiditis 29.2 IL10 TNF
28 bilirubin metabolic disorder 29.2 ALB F2 GPT
29 ulcerative colitis 29.2 IFNG IL10 TNF
30 colitis 29.2 IFNG IL10 TNF
31 primary biliary cirrhosis 29.2 ALB F2 SEPSECS
32 allergic rhinitis 29.2 HAVCR1 IFNG IL10
33 scrub typhus 29.2 GPT IL10 TNF
34 leptospirosis 29.2 F2 IFNG IL10 TNF
35 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 29.1 IFNG IKBKG IL10
36 poliomyelitis 29.1 IFNG IL10 TNF
37 aseptic meningitis 29.1 IFNG IL10 TNF
38 connective tissue disease 29.1 IFNG IL10 TNF
39 brucellosis 29.1 IFNG IL10 TNF
40 human immunodeficiency virus infectious disease 29.1 IFNG IL10 TNF
41 cholangitis, primary sclerosing 29.1 ALB GPT SEPSECS
42 graft-versus-host disease 29.1 IFNG IL10 TNF
43 demyelinating disease 29.1 IFNG IL10 TNF
44 rheumatic disease 29.0 IFNG IL10 TNF
45 chronic graft versus host disease 29.0 ALB IFNG IL10 TNF
46 meningitis 29.0 ALB IFNG IL10 TNF
47 asthma 28.9 F2 HAVCR1 IFNG IL10 TNF
48 dengue hemorrhagic fever 28.8 ALB F2 IFNG IL10 TNF
49 gastrointestinal system disease 28.6 AFP ALB F2 IFNG IL10 TNF
50 hemorrhagic fever 28.6 ALB F2 GPT IFNG IL10 TNF

Graphical network of the top 20 diseases related to Hepatitis a:



Diseases related to Hepatitis a

Symptoms & Phenotypes for Hepatitis a

Symptoms:

12
  • fever
  • vomiting
  • fatigue
  • abdominal pain
  • jaundice
  • nausea
  • joint pain
  • loss of appetite
  • clay-colored bowel movements

UMLS symptoms related to Hepatitis a:


nausea and vomiting, constipation, fever, abdominal pain, pruritus, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Hepatitis a:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.97 ABCB7 F2 IFNG IKBKG IL10 MAVS
2 homeostasis/metabolism MP:0005376 9.96 ABCB7 AFP ALB F2 IFNG IKBKG
3 digestive/alimentary MP:0005381 9.92 ALB F2 IFNG IKBKG IL10 MAVS
4 liver/biliary system MP:0005370 9.76 ABCB7 AFP ALB IFNG IKBKG IL10
5 mortality/aging MP:0010768 9.7 ABCB7 AFP ALB F2 HAVCR2 IFNG
6 neoplasm MP:0002006 9.17 AFP ALB IFNG IKBKG IL10 TICAM1

Drugs & Therapeutics for Hepatitis a

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Intron A 18 49 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
2
Cefazolin and Dextrose USP 18 CEFAZOLIN SODIUM B Braun Medical July 2000

Drugs for Hepatitis a (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 858)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93-14-1 3516
2
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 76-99-3 4095
3
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 142217-69-4 153941
4
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492
5
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
6
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 143491-57-0 60877
7
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 21645-51-2
8
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
9
Peginterferon alfa-2b Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 99210-65-8, 215647-85-1
10
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 36791-04-5 37542
11
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 142340-99-6 60871
12
Pyrazinamide Approved, Investigational Phase 4,Phase 2,Phase 3 98-96-4 1046
13
Isoniazid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 54-85-3 3767
14
Rifampicin Approved Phase 4,Phase 2,Phase 3,Phase 1 13292-46-1 5458213 5381226
15
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 198153-51-4 5360545
16
Tocopherol Approved, Investigational Phase 4,Phase 3,Not Applicable 1406-66-2 14986
17
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3424-98-4 159269
18
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134678-17-4 60825
19
Ezetimibe Approved Phase 4,Phase 3,Phase 2,Phase 1 163222-33-1 150311
20
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 111025-46-8 4829
21
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
22
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
23
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 155213-67-5 392622
24
leucovorin Approved Phase 4,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
25
Amantadine Approved Phase 4,Phase 3,Phase 2 768-94-5 2130
26
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
27
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 302-25-0
28
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 83-43-2 6741
29
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 50-24-8 5755
30
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 2921-57-5
31
Nitazoxanide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 55981-09-4 41684
32
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 174722-31-7 10201696
33
Ledipasvir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1256388-51-8 67505836
34
Sofosbuvir Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1190307-88-0 45375808
35
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
36 tannic acid Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
37
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
38
Ethiodized oil Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 8008-53-5
39
Pentoxifylline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 6493-05-6 4740
40
Chlorhexidine Approved, Vet_approved Phase 4,Not Applicable 55-56-1 2713 9552079
41
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 128-13-2 31401
42
glycyrrhizin Approved, Experimental Phase 4,Phase 3,Phase 2 1405-86-3 3495
43
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
44
Alprostadil Approved, Investigational Phase 4,Phase 2 745-65-3 149351 5280723
45
Simvastatin Approved Phase 4,Phase 2,Phase 3,Phase 1 79902-63-9 54454
46
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7440-66-6
47
Insulin glulisine Approved Phase 4 207748-29-6
48
Insulin Glargine Approved Phase 4 160337-95-1
49
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
50
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158

Interventional clinical trials:

(show top 50) (show all 4584)
# Name Status NCT ID Phase Drugs
1 PCV13 + Hepatitis A Vaccine for Adults Unknown status NCT01926860 Phase 4
2 A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults Unknown status NCT02203357 Phase 4
3 Combination Hepatitis A and B Vaccine to Induce Immunity in Non-responders Unknown status NCT01126853 Phase 4
4 Immunogenicity of Hepatitis B Vaccination in Hemodialysis Patients Unknown status NCT02963714 Phase 4
5 Immunogenicity of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients Unknown status NCT02991599 Phase 4
6 Immunogenicity of Hepatitis B Vaccination Among Drug Users Unknown status NCT02959775 Phase 4
7 Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma Unknown status NCT01765231 Phase 4 Entecavir prophylaxis;Observation arm
8 Adolescents' Response to Hepatitis B Vaccine Booster Dose Unknown status NCT01341275 Phase 4
9 Hepatitis C in Renal Transplant Recipients Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
10 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
11 Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders Unknown status NCT01451801 Phase 4
12 Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4 entecavir (BARACLUDE®)
13 Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4 pegylated IFN alfa-2b plus ribavirin
14 Entecavir Combined Short-term Intravenous Hepatitis B Immune Globulin (HBIG) to Prevent Hepatitis B Recurrence After Liver Transplantation Unknown status NCT02417207 Phase 4 Entecavir combined long-term low-dose HBIG group intramuscular;Entecavir combined HBIG group short-term high-dose intravenous
15 Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4 Entecavir;Entecavir, Adefovir;Entecavir, Adefovir
16 Hepatitis B Virus (HBV) Antibody (Anti-HBs) Booster Program for the Production of Hepatitis B Immune Globulin (HBIG) Unknown status NCT01311674 Phase 4
17 Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4 isoniazid, rifampin, pyrazinamide
18 Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B Unknown status NCT01925820 Phase 4 Pegasys&Entecavir
19 Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT Unknown status NCT01833611 Phase 4 Entecavir;placebo
20 Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine Unknown status NCT01548326 Phase 4 Atorvastatin;placebo
21 Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4 Continue NA treatment;Discontinue NA Treatment
22 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
23 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4 Pegasys plus Entecavir;Entecavir
24 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4 Emtricitabine
25 Emtricitabine for Naive Chinese Chronic Hepatitis B Patients Unknown status NCT02327663 Phase 4 Emtricitabine
26 Cognitive Impairments in Chronic Hepatitis C Patients and Potential Reversibility With New Agents (CICHepC) Unknown status NCT02745132 Phase 4
27 Twinrix Alternative Schedule Study Unknown status NCT00216229 Phase 4
28 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4 Ademetionine 2;Ademetionine 1;Ademetionine 3
29 Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy Unknown status NCT01595633 Phase 4 Switching from adefovir (10mg/day) to tenofovir (300mg/day)
30 Efficacy of Peginterferon Alpha 2a Therapy in Chronic Hepatitis B Patients Being Treated With Nucleoside(Acid) Analogues Unknown status NCT02362490 Phase 4 peginterferon alpha 2a
31 Antiviral Efficacy of the Combination Treatment With Poly IC and Entecavir for Chronic Hepatitis B Unknown status NCT02532413 Phase 4 Poly IC;Entecavir
32 Peginterferon Alfa-2b Treatment in HBeAg(+) Chronic Hepatitis b Patients Based on Interferon Gene Mutation and Receptor Detection Unknown status NCT02973646 Phase 4 Entecavir or Tenofovir;Peginterferon Alfa-2B
33 Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study Unknown status NCT01804387 Phase 4 telbivudine plus adefovir;lamivudine plus adefovir
34 Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C Unknown status NCT01649245 Phase 4 Reiferon retard
35 The Clinical Trial of the Anti Hepatitis B Placenta Transfer Factor Injection Unknown status NCT02412319 Phase 4 Anti-HBV placenta transfer factor injection
36 Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2) Unknown status NCT02768545 Phase 4 Ezetimibe
37 Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels Unknown status NCT00575627 Phase 4 Peg-Interferon alpha2a plus Ribavirin
38 Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients Unknown status NCT01439776 Phase 4
39 Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy Unknown status NCT01928511 Phase 4 peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly;Nucleos(t)ide analogue therapy
40 Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis Unknown status NCT02024295 Phase 4 Ademethionine;Polyene Phosphatidyl choline;Ademethionine
41 A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone Unknown status NCT00354653 Phase 4 LAMIVUDINE
42 Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B Unknown status NCT01906580 Phase 4 Peg-IFNα-2a;Entecavir
43 Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C Unknown status NCT02639585 Phase 4 Daclinza and Sunvepra
44 Study on Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults Unknown status NCT02822547 Phase 4 Peginterferon alfa-2a
45 The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin Unknown status NCT01025765 Phase 4 Pioglitazone;Acarbose;Metformin
46 Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B Unknown status NCT02482272 Phase 4 Lamivudine;Adefovir;Entecavir
47 Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4 Lamivudine
48 Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB) Unknown status NCT01380951 Phase 4 telbivudine
49 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
50 Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4 Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil

Search NIH Clinical Center for Hepatitis a

Cochrane evidence based reviews: hepatitis a

Genetic Tests for Hepatitis a

Anatomical Context for Hepatitis a

MalaCards organs/tissues related to Hepatitis a:

41
Liver, Testes, Kidney, T Cells, Bone, B Cells, Lung

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis a:

19
Liver

Publications for Hepatitis a

Articles related to Hepatitis a:

(show top 50) (show all 1720)
# Title Authors Year
1
Outbreak of Hepatitis A Virus Infection Among Adult Patients of a Mental Hospital-Los Angeles County, 2017 - CORRECTION. ( 29970205 )
2018
2
Complement factor 3 among children with hepatitis A: Assessment of bilirubin levels. ( 29371712 )
2018
3
Minocycline-associated polyarteritis nodosa and self-limiting hepatitis: a reminder of a potentially re-emerging culprit in drug-induced autoimmune syndromes. ( 29532736 )
2018
4
Metagenomic analysis reveals Hepatitis A virus in suspected yellow fever cases in Brazil. ( 29211109 )
2018
5
Travel-associated hepatitis A in Europe, 2009 to 2015. ( 29871720 )
2018
6
Hepatitis A, cardiomyopathy, aplastic anemia, and acute liver failure: A devastating scenario. ( 29359844 )
2018
7
Serologic differential diagnosis of hepatitis A virus (HAV) infected and vaccinated individuals: How long persist antibodies to non-structural HAV proteins? ( 29907320 )
2018
8
Duck hepatitis A virus structural proteins expressed in insect cells self-assemble into virus-like particles with strong immunogenicity in ducklings. ( 29426402 )
2018
9
Comparative liver transcriptome analysis in ducklings infected with duck hepatitis A virus 3 (DHAV-3) at 12 and 48A hours post-infection through RNA-seq. ( 29925406 )
2018
10
Psychological Disorders and Quality of Life Among Patients With Chronic Viral Hepatitis: A Single-Center Cross-Sectional Study With Pair-Matched Healthy Controls. ( 29847395 )
2018
11
Natural History, Clinical Manifestations, and Pathogenesis of Hepatitis A. ( 29440324 )
2018
12
Comparative efficacy and tolerability of treatments for adult autoimmune hepatitis: A systematic review and network meta-analysis. ( 29904396 )
2018
13
Hepatitis A vaccination coverage among adolescents (13-17a8^years) in the United States, 2008-2016. ( 29449100 )
2018
14
The impact of expanded program on immunization with live attenuated and inactivated Hepatitis A vaccines in China, 2004-2016. ( 29398275 )
2018
15
Lost in Inflammation: The Functional Conversion of Regulatory T Cells in Acute Hepatitis A Virus Infection. ( 29427580 )
2018
16
A Case of Graves' Disease Accompanied with Acute Hepatitis A Virus Infection. ( 29943563 )
2018
17
Extracorporeal Cellular Therapy (ELAD) in Severe Alcoholic Hepatitis- A Multinational, Prospective, Controlled, Randomized Trial. ( 29385313 )
2018
18
Pathogenicity of duck hepatitis A virus type 3 and innate immune responses of the ducklings to virulent DHAV-3. ( 29407574 )
2018
19
Hepatitis A and hepatitis B vaccination coverage among adults with chronic liver disease. ( 29395521 )
2018
20
Examining Hepatitis, A and B Vaccination, and HBV Reactivation Monitoring During Direct-Acting Antiviral Therapy for Hepatitis C. ( 29846860 )
2018
21
Immunization Against Hepatitis A Virus and Hepatitis B Virus in Patients with Chronic Liver Disease: Are We Doing a Good Job? ( 29942730 )
2018
22
Evidence of hepatitis A virus infection in the patients with acute encephalitis syndrome in Gorakhpur region, North India. ( 29895163 )
2018
23
Lumbar synovial cyst with chronic viral hepatitis: A case series and literature review. ( 29724648 )
2018
24
Experimental infection of Marmota monax with a novel hepatitis A virus. ( 29387970 )
2018
25
Relationship of Severity of Hepatitis A with Polymorphisms in Hepatitis A Virus Cellular Receptor 1 (HAVCR1) Gene. ( 29893695 )
2018
26
An outbreak of acute hepatitis A among young adult men: clinical features and HIV coinfection rate from a large teaching hospital in Rome, Italy. ( 29380498 )
2018
27
Tumor Necrosis Factor-producing T-regulatory Cells AreA Associated With Severe Liver Injury in Patients With AcuteA Hepatitis A. ( 29229400 )
2018
28
Hepatitis A, B, and A/B vaccination series completion among US adults: a claims-based analysis. ( 29923789 )
2018
29
Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series. ( 29406396 )
2018
30
Protective efficacy of a bivalent live attenuated vaccine against duck hepatitis A virus types 1 and 3 in ducklings. ( 29408021 )
2018
31
Spillover of a hepatitis A outbreak among men who have sex with men (MSM) to the general population, the Netherlands, 2017. ( 29897040 )
2018
32
Group C Streptococcal Sore Throat with Hepatitis - a Rare Association. ( 29870104 )
2018
33
Response to comment on: Validation of HAV biomarker 2A for differential diagnostic of hepatitis A infected and vaccinated individuals using multiplex serology. ( 29907321 )
2018
34
Improved TaqMan real-time assays for detecting hepatitis A virus. ( 29409997 )
2018
35
Liver transplantation for alcoholic hepatitis: A systematic review with meta-analysis. ( 29324766 )
2018
36
Family occurrence of autoimmune hepatitis: A Danish nationwide registry-based cohort study. ( 29885414 )
2018
37
HAVCR1 (CD365) and its mouse ortholog are functional hepatitis A virus (HAV) cellular receptors that mediate HAV infection. ( 29437974 )
2018
38
Acute hepatitis A breakthrough in MSM in Paris area: implementation of targeted hepatitis A virus vaccine in a context of vaccine shortage. ( 29381561 )
2018
39
Clinical and virological features of acute hepatitis A during an ongoing outbreak among men who have sex with men in the North of France. ( 29886426 )
2018
40
Leucopenia: A Rare Extrahepatic Manifestation of Acute Hepatitis A. ( 29892189 )
2018
41
Decrease in seroprevalence of hepatitis A virus in Santiago, Chile: A decade-long comparison. ( 29871761 )
2018
42
A Novel Model to Predict 1-Month Risk of Transplant or Death in Hepatitis A-Related Acute Liver Failure. ( 30194739 )
2018
43
Outcome comparison of liver transplantation for hepatitis A-related versus hepatitis B-related acute liver failure in adult recipients. ( 29044729 )
2018
44
Potential triggering factors of acute liver failure as a first manifestation of autoimmune hepatitis-a single center experience of 52 adult patients. ( 29632422 )
2018
45
A Very Rare Complication of Hepatitis A Infection: Acute Myocarditis-A Case Report with Literature Review. ( 30302093 )
2018
46
Causal relationship between acute pancreatitis and methylprednisolone pulse therapy for fulminant autoimmune hepatitis: a case report and review of literature. ( 29881634 )
2018
47
Acute alcoholic hepatitis: a literature review and proposal of treatment. ( 29115798 )
2018
48
Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial. ( 29171941 )
2018
49
Extracorporeal liver assist device for alcoholic hepatitis: A potential silver lining? ( 29365343 )
2018
50
Mortality and costs associated with alcoholic hepatitis: A claims analysis of a commercially insured population. ( 30048829 )
2018

Variations for Hepatitis a

Expression for Hepatitis a

Search GEO for disease gene expression data for Hepatitis a.

Pathways for Hepatitis a

Pathways related to Hepatitis a according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.7 IFNG IKBKG IL10 MAVS TICAM1 TNF
2
Show member pathways
12.6 IFNG IKBKG MAVS TICAM1 TNF
3
Show member pathways
12.56 IFNG IKBKG MAVS TICAM1 TNF
4
Show member pathways
12.49 IFNG IKBKG IL10 TNF
5
Show member pathways
12.44 IFNG IKBKG IL10 TNF
6
Show member pathways
12.28 IFNG IKBKG IL10 TNF
7
Show member pathways
12.19 F2 IFNG IKBKG IL10 TNF
8
Show member pathways
12.16 IFNG IKBKG TICAM1 TNF
9
Show member pathways
12.16 ALB F2 IFNG TNF
10
Show member pathways
12.03 IFNG IKBKG IL10 TNF
11 11.96 IFNG IKBKG TNF
12
Show member pathways
11.92 IFNG IL10 TNF
13 11.91 IFNG IKBKG TNF
14
Show member pathways
11.89 F2 IFNG TNF
15 11.85 IFNG IL10 TNF
16 11.76 IFNG IL10 TNF
17 11.75 IKBKG TICAM1 TNF
18 11.74 HAVCR1 HAVCR2 IFNG IKBKG IL10 MAVS
19 11.66 IFNG IL10 TNF
20 11.63 IL10 TICAM1 TNF
21 11.59 IFNG IL10 TNF
22 11.57 IKBKG MAVS TICAM1 TNF
23 11.56 IFNG IL10 TNF
24
Show member pathways
11.35 IFNG IKBKG TNF
25 11.3 IFNG IL10 TNF
26 11.22 AFP ALB F2
27 11.04 IFNG IL10 TNF
28 11.03 IKBKG TNF
29 11.03 IKBKG TICAM1
30 11 IKBKG TNF
31 10.59 IFNG IL10 TNF

GO Terms for Hepatitis a

Cellular components related to Hepatitis a according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.17 AFP ALB F2 GPT IFNG IL10

Biological processes related to Hepatitis a according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.82 IKBKG TICAM1 TNF
2 positive regulation of DNA-binding transcription factor activity GO:0051091 9.78 IL10 MAVS TNF
3 positive regulation of protein phosphorylation GO:0001934 9.78 F2 IFNG MAVS TNF
4 response to virus GO:0009615 9.77 IFNG IKBKG TNF
5 inflammatory response GO:0006954 9.77 HAVCR2 IKBKG IL10 TICAM1 TNF
6 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.76 IKBKG MAVS TICAM1 TNF
7 cellular response to lipopolysaccharide GO:0071222 9.73 HAVCR2 IL10 TICAM1 TNF
8 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.7 IKBKG TICAM1 TNF
9 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.65 IKBKG TICAM1
10 protein import into nucleus, translocation GO:0000060 9.65 IFNG TNF
11 positive regulation of osteoclast differentiation GO:0045672 9.64 IFNG TNF
12 positive regulation of chemokine production GO:0032722 9.63 HAVCR2 TNF
13 positive regulation of macrophage activation GO:0043032 9.63 HAVCR2 IL10
14 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.62 IFNG TNF
15 negative regulation of growth of symbiont in host GO:0044130 9.62 IL10 TNF
16 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.61 IL10 TNF
17 positive regulation of tumor necrosis factor secretion GO:1904469 9.59 HAVCR2 MAVS
18 positive regulation of protein import into nucleus, translocation GO:0033160 9.58 IFNG MAVS
19 MyD88-independent toll-like receptor signaling pathway GO:0002756 9.58 IKBKG TICAM1
20 positive regulation of nitric oxide biosynthetic process GO:0045429 9.58 IFNG TICAM1 TNF
21 toll-like receptor 3 signaling pathway GO:0034138 9.57 HAVCR2 TICAM1
22 macrophage activation involved in immune response GO:0002281 9.56 HAVCR2 TICAM1
23 endothelial cell apoptotic process GO:0072577 9.55 IL10 TNF
24 positive regulation of chemokine biosynthetic process GO:0045080 9.54 TICAM1 TNF
25 negative regulation of cytokine secretion involved in immune response GO:0002740 9.51 IL10 TNF
26 positive regulation of myeloid dendritic cell cytokine production GO:0002735 9.49 MAVS TICAM1
27 negative regulation of myeloid dendritic cell activation GO:0030886 9.32 HAVCR2 IL10
28 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.26 IFNG TNF
29 receptor biosynthetic process GO:0032800 9.16 IL10 TNF
30 positive regulation of vitamin D biosynthetic process GO:0060557 8.96 IFNG TNF
31 negative regulation of interleukin-6 production GO:0032715 8.8 HAVCR2 IL10 TNF

Sources for Hepatitis a

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....